Wellington Management Group’s ANI Pharmaceuticals ANIP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$583K Sell
7,048
-495
-7% -$39.7K ﹤0.01% 1819
2026
Q1
$580K Sell
7,543
-354
-4% -$27.6K ﹤0.01% 1760
2025
Q4
$623K Sell
7,897
-275
-3% -$23.8K ﹤0.01% 1793
2025
Q3
$749K Buy
8,172
+291
+4% +$23.7K ﹤0.01% 1829
2025
Q2
$514K Sell
7,881
-325
-4% -$21.2K ﹤0.01% 1819
2025
Q1
$549K Buy
+8,206
New +$490K ﹤0.01% 1808
2024
Q4
– Sell
-9,411
Closed -$561K – 1938
2024
Q3
$561K Sell
9,411
-34,218
-78% -$2.09M ﹤0.01% 1804
2024
Q2
$2.78M Buy
43,629
+2,899
+7% +$188K ﹤0.01% 1450
2024
Q1
$2.82M Buy
40,730
+31,408
+337% +$1.9M ﹤0.01% 1451
2023
Q4
$514K Buy
+9,322
New +$513K ﹤0.01% 1725
2015
Q2
– Sell
-8,926
Closed -$559K – 2135
2015
Q1
$559K Sell
8,926
-7,825
-47% -$476K ﹤0.01% 1961
2014
Q4
$944K Buy
+16,751
New +$739K ﹤0.01% 1869

Other funds holding ANIP

Wellington Management Group's ANIP Position: Q2 2026 in Review

Wellington Management Group reduced its ANI Pharmaceuticals (ANIP) stake by 6.6% in Q2 2026, selling an estimated $39.7K and leaving 7,048 shares worth $583K. The position accounts for ﹤0.01% of the portfolio, ranked #1819.

Wellington Management Group first reported a position in ANIP in Q4 2014 and has held it in 12 quarters since. The position peaked at $2.82M in Q1 2024. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Wellington Management Group held 7,048 shares of ANI Pharmaceuticals worth $583K as of Q2 2026.
  • Wellington Management Group sold 495 ANI Pharmaceuticals shares in Q2 2026, an estimated $39.7K.
  • ANI Pharmaceuticals made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1819 holding.
  • Wellington Management Group first reported a position in ANI Pharmaceuticals in Q4 2014 and has held it in 12 quarters since.
  • Wellington Management Group's ANI Pharmaceuticals position peaked at $2.82M in Q1 2024.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.